- Investing Ideas
- Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swiss Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
6
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
6 companies
Galderma Group
Market Cap: CHF 40.5b
Operates as a dermatology company worldwide.
GALD
CHF 172.95
7D
1.3%
1Y
36.9%
Sandoz Group
Market Cap: CHF 28.4b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 64.96
7D
-2.6%
1Y
41.4%
Bachem Holding
Market Cap: CHF 5.3b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 70.25
7D
-5.6%
1Y
21.1%
Tecan Group
Market Cap: CHF 2.3b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 178.70
7D
-2.3%
1Y
13.0%
Idorsia
Market Cap: CHF 1.5b
A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.
IDIA
CHF 6.10
7D
0.3%
1Y
104.7%
Basilea Pharmaceutica
Market Cap: CHF 642.1m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 51.50
7D
-3.0%
1Y
-3.9%